ETFs Harmony Biosciences Holdings, Inc.

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-16 pm EST			5-day change	1st Jan Change
38.83 ^USD	-0.23%		+0.03%	+12.85%

Dec. 16	Harmony Biosciences, Beacon Biosignals Collaborate on Phase 3 Trials in Narcolepsy, Hypersomnia	MT
Dec. 16	Beacon Biosignals announces partnership with Harmony Biosciences	RE

ETFs positioned on Harmony Biosciences Holdings, Inc.

Name	Weight	AuM	Varia. Jan 1.	Investor
HARTFORD MULTIFACTOR SMALL CAP ETF - USD	0.35%	29 M€	+10.44%	-
ROYCE QUANT SMALL-CAP QUALITY VALUE ETF - USD	0.31%	22 M€	+3.13%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.01%	51 M€	+4.72%	-
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD	0%	7 M€	+14.41%	-
VANGUARD US TOTAL MARKET SHARES INDEX ETF	0%	293,477 M€	+7.42%	-
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD	0%	31 M€	+2.84%	-

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Employees

268

Sector

Pharmaceuticals

Calendar

Mar. 02 - Q4 2025 Earnings Release (Projected)

More about the company